2 hours ago
HomeMarket NewsStrides Pharma Q3 Results: Stock surges after Co maintains US biz outlook, margins expand
Strides Pharma's Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) for the quarter grew by 12.2% year-on-year to ₹235.8 crore, while margins expanded by 150 basis points to 19.7% from 18.2% last year.
Shares of Strides Pharma Ltd. gained over 2.5% on Friday, January 30, in response to its December quarter results.
US sales for the company stood at $70 million, nearly the same figure of $73 million during the same quarter last year. The company has also reiterated its US business revenue outlook of $400 million by financial year 2028.
For the December quarter, Strides Pharma reported a net profit of ₹202 crore from ₹88 crore during the same quarter last year.
Revenue for the quarter stood at ₹1,194.6 crore, 3.6% higher than the ₹1,153.6 crore during the year-ago period.
Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) for the quarter grew by 12.2% year-on-year to ₹235.8 crore, while margins expanded by 150 basis points to 19.7% from 18.2% last year.
Shares of Strides Pharma are now trading 6% higher after the earnings announcement at ₹857. The stock is up 30% in the last 12 months.
